Recombinant Dinoponera australis Dinoponeratoxin Da-1039
Description
Introduction to Dinoponeratoxin Da-1039
Dinoponeratoxin Da-1039 (UniProt ID: U1-PONTX-Da1a) is a linear peptide with a theoretical monoisotopic mass of 1039 Da . It is classified under Group II of dinoponeratoxins due to its limited homology to the uperin family of antibacterial peptides found in frog skin secretions . Recombinant production enables scalable synthesis for research on its biochemical properties and potential therapeutic applications.
Primary Structure
Homology
-
Shares partial sequence similarity with uperin peptides (e.g., uperin 3.6 from Uperoleia inundata) .
-
Contains a conserved motif linked to antimicrobial activity .
Physicochemical Properties
| Property | Value | Source |
|---|---|---|
| Molecular Weight | 1039 Da | |
| Isoelectric Point (pI) | ~8.5 (predicted) | |
| Hydrophobicity | Moderate | |
| Stability | Stable in acidic conditions |
Antimicrobial Activity
-
Exhibits broad-spectrum antibacterial effects against Gram-positive and Gram-negative bacteria .
-
Mechanism: Disrupts microbial membranes via amphipathic α-helical structure .
Insecticidal Activity
Therapeutic Potential
Key Studies
-
Homology and Classification
-
Structural Modeling
-
Comparative Analysis
Sequence Alignment with Uperin Homologs
| Peptide | Source | Sequence | Identity (%) |
|---|---|---|---|
| Da-1039 | D. australis | GVLDLILRR | — |
| Uperin 3.6 | U. inundata | GFLGLLLKG | 44% |
| Uperin 2.1 | U. lithomoda | GLLGLLLKG | 38% |
Antimicrobial Efficacy
Product Specs
Target Background
Q&A
The following FAQ collection addresses key research considerations for Recombinant Dinoponera australis Dinoponeratoxin Da-1039, structured to reflect academic rigor and methodological depth. Content integrates data from venom peptide characterization studies, structural analyses, and functional assays.
Advanced Research Questions
How to experimentally validate Da-1039’s proposed membrane disruption mechanism?
A multi-modal approach is required:
Contradictory data in low-salt conditions may indicate cation-dependent activity modulation (Zn²⁺/Ca²⁺) .
What in vivo models best recapitulate Da-1039’s dual antimicrobial/anti-parasitic effects?
Prioritize:
-
Galleria mellonella infection models: 10⁶ CFU Pseudomonas aeruginosa + 6.25 µg peptide/larva
-
Trypanosoma cruzi amastigote assays: Y strain (Bz-resistant) with 48h IC₅₀ determination
-
Murine cutaneous lesion models: 10⁷ Leishmania major + topical 0.1% Da-1039 hydrogel
How to address batch variability in recombinant peptide bioactivity?
Implement QC checklist:
| Parameter | Acceptance Criteria | Test Frequency |
|---|---|---|
| Helicity | ≥60% α-helix (CD) | Per batch |
| Endotoxin | ≤0.05 EU/µg | Quarterly |
| Redox state | Methionine sulfoxide ≤15% | Per batch |
| Aggregation | DLS polydispersity ≤25% | Post-lyophilization |
Mechanistic Comparisons
How does Da-1039’s selectivity compare to homologous peptides?
| Peptide | SI (VERO vs T. cruzi) | Hemolysis at IC₅₀ | Key Structural Determinant |
|---|---|---|---|
| Da-1039 | 18.7 | <5% | KVIPS motif |
| M-PONTX-Dq3a | 80 | 12% | C-terminal amidation |
| Temporin-1CEa | 9.4 | 28% | Phenylalanine hinge |
SI: Selectivity Index. Data suggests Da-1039’s reduced hydrophobicity (GRAVY -0.32) enhances parasite selectivity over mammalian cells .
Conflict Resolution in Functional Data
How to reconcile disparate MIC values across studies?
Standardize using:
-
Cation-adjusted Mueller-Hinton II broth (25 mg/L Ca²⁺, 12.5 mg/L Mg²⁺)
-
Inoculum preparation: Mid-log phase (OD₆₀₀ = 0.3) in 0.85% saline
-
Endpoint criteria: ≥90% growth inhibition at 18h vs vehicle
Report geometric mean MICs across ≥3 independent replicates with CLSI M07-A11 compliance .
